From New Mechanisms to New Standards of Care
Focusing on Improving Patient Outcomes in Infectious Diseases
Latest News
News / 18 Jun 2019
Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option
News / 12 Jun 2019
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
News / 14 Apr 2019
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
We are building a very different antibiotics company that focuses on bringing innovation to antibiotic development. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
Chief Executive Officer
2019 AGM
The AGM will be held on 19 June 2019 and more information is available from the dedicated page in the investors section
Latest Event
Slingshot Insights Management Call
Our Discuva Platform
Our technology platform is at the heart of our research to develop new mechanism antibiotics